BioVie Inc (BIVI)

[02opida]

SANTA MONICA, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader (KOL) webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer’s Disease on Tuesday, October 26, 2021 at 1:30 pm Eastern Time.

The webinar will feature presentations by KOLs Jefferson Kinney, Ph.D., University of Nevada, Las Vegas, who will discuss the basis of inflammation as a central mechanism in Alzheimer’s disease, and Karl Herrup, Ph.D., University of Pittsburgh School of Medicine, who will discuss the importance of age-related hyperinsulinemia and brain insulin resistance in neurodegeneration.

BioVie's management team will also discuss NE3107 for the treatment of Alzheimer's disease. NE3107’s mechanism acts on both the fundamental inflammatory signaling pathways and the consequent insulin resistance that are the root causes of Alzheimer’s and other neurodegenerative diseases. BioVie recently announced that the Company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer’s Disease (AD). The NM101 study is a potentially pivotal Phase 3, randomized, double-blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD.